What will Dr. Iman Barilero do for Oryzon Genomics, S.A.?

Dr. Iman Barilero will advise Oryzon Genomics, S.A. on regulatory affairs. The company said her role will support its Medical, Regulatory, and Strategic functions as it advances vafidemstat and its wider CNS pipeline.

When did Oryzon Genomics, S.A. announce the collaboration with Dr. Iman Barilero?

Oryzon Genomics, S.A. announced the collaboration on October 28th, 2025. The announcement was made from Madrid, Spain and Cambridge, MA, United States.

Why has Oryzon Genomics, S.A. appointed Dr. Iman Barilero as Senior Advisor for Regulatory Affairs?

Oryzon Genomics, S.A. said Dr. Barilero’s expertise will support the advancement of vafidemstat into Phase III and help address all areas identified by the FDA. CEO Dr. Carlos Buesa said her leadership will help the company prepare to advance its late-stage pipeline in BPD and schizophrenia, as well as its early-stage programme in Autistic Spectrum Disorder (ASD).

What regulatory experience does Dr. Iman Barilero bring to Oryzon Genomics, S.A.?

Dr. Iman Barilero brings over 30 years of global regulatory leadership across CNS, neuropsychiatry, immuno-oncology, and rare diseases. Oryzon said she has guided Phase II–III programmes, secured global approvals, developed regulatory pathways, and engaged directly with the FDA, EMA, PMDA, CFDA, Health Canada, ANVISA, and other health authorities.

What was Dr. Iman Barilero’s previous role at Lundbeck?

Dr. Iman Barilero was Vice President, Head of Global Regulatory Science for CNS at Lundbeck. Oryzon said she led global regulatory strategies for therapies targeting depression, bipolar disorder, schizophrenia, stroke, Alzheimer’s disease, Parkinson’s disease, and alcohol dependence.

What did Oryzon Genomics, S.A. say about Dr. Iman Barilero’s regulatory achievements?

Oryzon Genomics, S.A. said Dr. Barilero played a pivotal role in securing first-in-class label claims for cognition in major depressive disorder for Brintellix/Trintellix. The company also said she helped secure approvals across the US, EU, Japan, China, and other major markets.

What is Oryzon Genomics, S.A.’s vafidemstat programme currently assessing?

Vafidemstat is currently being evaluated in EVOLUTION, a double-blind, randomized, placebo-controlled Phase IIb trial. The trial is assessing its potential to improve negative symptoms in schizophrenia.

What other CNS programmes does Oryzon Genomics, S.A. have?

Oryzon Genomics, S.A.’s CNS pipeline includes programmes in schizophrenia and Autistic Spectrum Disorder (ASD), in addition to its BPD programme. The company said a clinical trial in ASD is also in preparation.

Where are Oryzon Genomics, S.A.’s shares listed and what is the ticker symbol?

Oryzon Genomics, S.A. is identified in the announcement by ISIN Code: ES0167733015 and BME: ORY.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon appoints Dr. Iman Barilero as Senior Advisor for Regulatory Affairs

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon appoints Dr. Iman Barilero as Senior Advisor for Regulatory Affairs

Published Tuesday, 28 October 2025

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Management change
Published: Tuesday, 28 October 2025
Source announcement: oryzon.com

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics, S.A. (BME: ORY) announced a collaboration with Dr. Iman Barilero, PharmD, PhD, who has been appointed Senior Advisor for Regulatory Affairs.

The company said Dr. Barilero will support advancement of its Phase III clinical program for vafidemstat in Borderline Personality Disorder and address areas identified by the FDA. Her remit also covers the company’s late-stage pipeline in schizophrenia and early-stage program in Autistic Spectrum Disorder. Oryzon said vafidemstat is being evaluated in the EVOLUTION Phase IIb trial in schizophrenia, while an ASD clinical trial is in preparation.

Investor FAQs

Oryzon Genomics, S.A. announced a strategic collaboration with Dr. Iman Barilero, PharmD, PhD, who will serve as Senior Advisor for Regulatory Affairs. The collaboration is intended to support the advancement of Oryzon’s Phase III clinical programme with vafidemstat in Borderline Personality Disorder (BPD).

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON strengthens regulatory strategy with the appointment of Dr. Iman Barilero as Senior Advisor for Regulatory Affairs
Published: Tuesday, 28 October 2025
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…